Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07401225

TMS for PTSD in Youth

The purpose of this study is to test whether transcranial magnetic stimulation, or TMS, is an acceptable and helpful treatment for ongoing symptoms of posttraumatic stress syndrome disorder (PTSD) in 12-20 year olds. Ongoing PTSD refers to symptoms that continue after completing trauma-focused psychotherapy. About 1 in 4 patients need additional help to overcome PTSD after completing psychotherapy. Currently, scientists do not know the best way to help adolescents with persistent PTSD, and this study will test TMS as a possible treatment, and hopefully lead to future studies including more people.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UT Health Department of Psychiatry

San Antonio, Texas, 78229, United States

Location status: Recruiting

Location contact

Amy Garrett, PhD

CONTACT

[email protected]

210-567-8189

About this study

Trauma is a common occurrence among youth. Almost 60% of American youths experience a traumatic event before age 18, such as physical or sexual abuse, sudden loss of caregivers, or witnessing violence in the community or the home. Distress after a significantly traumatic event is to be expected, but for some youths, symptoms of posttraumatic stress disorder (PTSD) linger for months or years, and can become chronic if left untreated. Symptoms of PTSD can include upsetting memories, avoidance of reminders, and emotional numbing, and other symptoms. These symptoms can create difficulties for family relationships, friendships, and schoolwork. Currently, the most effective treatment for PTSD is talk therapy (trauma-focused psychotherapy). However, sometimes young people continue to have symptoms of PTSD after completing talk therapy, and it is currently not known the best way to help with these persistent symptoms.

In this study, the total length of time participants will be involved in the study is about 16-weeks. During that time, participants will be asked to attend approximately 6 research visits and 10 treatment visits, for a total of 16 visits. The 6 research visits include a screening visit, an interview visit, 2 MRI visits, and 2 follow-up visits. The screening, interview, and follow-up visits can be completed virtually, over zoom. The study will include 2 MRI visits and 10 treatment visits. Virtual follow-up visits will be conducted 1 and 3 months after completion of treatment and will include interviews and questionnaires about participants symptoms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females; Age 12-20
  • Have previously completed at least 9 sessions of trauma-focused therapy in our clinical trial or in the community
  • Have current self-reported symptom score of 20 or greater on the UCLA PTSD Reaction index
  • Willing to attend 10 TMS treatment sessions within a 30-day period
  • Fluent in English

Exclusion criteria

  • History of seizures
  • History of head injury with loss of consciousness and concussive sequelae
  • Brain abnormality such as tumor or other observable abnormality
  • Currently receiving psychotherapy or TMS treatment
  • Currently pregnant
  • MRI contraindications (metal in body, orthodontic braces)
  • Diagnosis of bipolar 1 or a psychotic disorder

Treatment and study plan

MagPro R30 with robotic arm

Device

TMS will be delivered to the right anterior dorsolateral frontal cortex. The accelerated protocol consists of 1,800 TMS pulses per session, delivered at intensity ranges designed to deliver depth-corrected E-fields of 80-95 volts/meter. The exact intensity will be determined when the participant's treatment plan is developed. Once a patient's TMS treatment plan has been created, it will be used for every treatment session for that participant.

Primary outcomes

  1. Side Effects of TMS treatment

    Time frame: Day 1 of treatment through Day 30

    number of side effects reported per participant

  2. Number of Adverse Events

    Time frame: Day 1 of treatment through Day 30

    Number of adverse events experienced by study participants through the treatment phase of the study

  3. Completion rate of Treatment

    Time frame: Day 1 of treatment through Day 30

    Number of participants that completed the TMS treatment

Secondary outcomes

  1. Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)(CAPS-5)

    Time frame: Baseline to 90 days

    The CAPS-5 score range for total symptom severity is 0 to 80, calculated by summing the severity ratings (0-4) for 20 PTSD symptoms, with higher scores indicating greater severity; scores below 31-33 often suggest subclinical or non-diagnostic levels, while scores above this range can indicate probable PTSD.

  2. Assessment of Depression using Patient Health Questionnaire-9 (PHQ-9)

    Time frame: Baseline to Day 30

    Patients rate 9 common depressive symptoms (e.g., feeling down, trouble sleeping, low energy, poor appetite, concentration issues, feeling bad about self, restlessness/slowed down, thoughts of being better off dead/hurting self).

    Scoring: Each symptom gets 0-3 points, totaling 0-27. A lower score indicates less depression.

Study contacts

Contact information is provided by the study sponsor or research team.

Amy S Garrett, PhD

CONTACT

[email protected]

210-567-8189

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center at San Antonio

Other

Collaborators

  • Texas Child Mental Health Care Consortium: TCMHCC

Registry information

Official study title

Transcranial Magnetic Stimulation as Treatment for Persistent PTSD in Texas Youth

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 10, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.